Antiviral Drugs: Mechanisms, Indications, Clinical Evidence and Safety

Medical education review; updated 10 November 2026. Regimens must be individualized and checked against local guidelines.

Overview

Antiviral drugs target specific viral enzymes or replication stages; they do not work interchangeably across viral infections. Selection depends on the infecting virus, disease severity, timing, host immune status, resistance and renal/hepatic function [1,2].

Classification and mechanisms

  • Herpesviruses: acyclovir and valacyclovir inhibit viral DNA polymerase after activation, primarily by viral thymidine kinase in HSV/VZV; ganciclovir/valganciclovir cover CMV, with marrow suppression risk. Foscarnet directly inhibits DNA polymerase without requiring viral kinase activation.
  • Influenza: oseltamivir, zanamivir and peramivir inhibit neuraminidase; baloxavir inhibits the cap-dependent endonuclease of influenza polymerase [1].
  • SARS-CoV-2: nirmatrelvir inhibits the viral main protease and is combined with ritonavir to increase exposure; remdesivir inhibits RNA-dependent RNA polymerase. Molnupiravir induces viral RNA replication errors and is a less-preferred alternative [2].
  • Hepatitis B: tenofovir and entecavir inhibit HBV reverse transcriptase/polymerase and typically suppress rather than eradicate chronic infection.
  • Hepatitis C: direct-acting antiviral combinations inhibit NS3/4A protease, NS5A or NS5B polymerase; modern regimens can cure most patients, with selection based on cirrhosis, prior therapy and interactions.
  • HIV: a separate combination-ART framework is needed; ritonavir is a protease inhibitor/booster, not a capsid inhibitor.

When treatment is most effective

For influenza, high-risk, hospitalized or progressive cases should receive prompt therapy without waiting for laboratory confirmation. Early treatment provides greatest benefit, but hospitalized and severely ill patients can benefit after 48 hours [1]. For higher-risk nonhospitalized patients with COVID-19, initiate nirmatrelvir/ritonavir within five days of symptom onset or three-day intravenous remdesivir within seven days when eligible [2].

Safety and interactions

Acyclovir and valacyclovir require renal adjustment and hydration assessment; intravenous acyclovir can cause crystal-associated kidney injury. Ganciclovir may suppress neutrophils and platelets. Zanamivir inhalation may provoke bronchospasm in patients with airway disease. Oseltamivir commonly causes nausea. Baloxavir absorption is reduced by polyvalent cations. Ritonavir has major CYP3A-mediated interactions with antiarrhythmics, anticoagulants, anticonvulsants, immunosuppressants and certain statins; run a drug-interaction check before prescribing [1,2].

Special populations and resistance

Immunocompromised patients may need longer treatment, diagnostic testing and specialist review. Drug resistance can emerge during inadequate exposure or prolonged replication; obtain viral susceptibility testing when clinically relevant. Pregnancy and pediatric dosing are agent-specific; do not generalize across antivirals [1,2].

Clinical pearls

Antibiotics do not treat viral infections. Vaccination remains foundational, antivirals do not replace it, and prophylaxis is appropriate only for specified viruses and populations. Avoid misleading blanket statements that all nucleoside analogues are activated identically or that one antiviral treats multiple unrelated viruses.

References

  1. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Updated 2026 Mar 10. Available from: https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html
  2. Centers for Disease Control and Prevention. COVID-19 treatment clinical care for outpatients. Updated 2026 Oct 8. Available from: https://www.cdc.gov/covid/hcp/clinical-care/outpatient-treatment.html
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *